Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
  1. Home
  2. Publications
  3. Supplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors

Supplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors

Authors:
  • EFEdward Favours
    Edward Favours
  • HTHaiying Tang
    Haiying Tang
  • PWPeyton Wong
    Peyton Wong
  • SGSamuel Ghilu
    Samuel Ghilu
  • VPVanessa del Pozo
    Vanessa del Pozo
  • EMElena Mironova
    Elena Mironova
  • YCYidong Chen
    Yidong Chen
  • TSTim Stearns
    Tim Stearns
  • SNSteven Neuhauser
    Steven Neuhauser
  • EEEric J. Earley
    Eric J. Earley
  • SEStephen W. Erickson
    Stephen W. Erickson
  • JKJee Young Kwon
    Jee Young Kwon

Open Access
Publisher website
Google Scholar
  • 17 July 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.33014409
Abstract
Efficacy testing summary results for MRT models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
Keywords
  • DRUG TARGETS
  • CELL SURFACE RECEPTOR DRUG TARGETS
  • IMMUNOTHERAPY
  • ANTIBODY IMMUNOTHERAPY
  • PEDIATRIC CANCERS
  • PRECLINICAL MODELS
  • ANIMAL MODELS OF CANCER
  • XENOGRAFT MODELS
  • RARE CANCERS
  • SARCOMAS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.